1. Introduction

Taxation of Genetic Data Transactions is an emerging area of biotechnology, intellectual property, digital commerce, healthcare regulation and international tax law. It concerns the tax consequences arising when genetic information is collected, processed, licensed, transferred, commercialised, exchanged or monetised.

Genetic data includes information obtained from DNA sequencing, genome analysis, hereditary testing, genetic profiling, ancestry databases, genomic research and other biological information capable of identifying or revealing characteristics of an individual.

Genetic data has considerable commercial value. Pharmaceutical companies, biotechnology enterprises, hospitals, genetic-testing laboratories, research institutions and artificial intelligence companies may enter into transactions involving such information.

Examples include:

Licensing genomic databases to pharmaceutical companies.

Selling access to genetic research datasets.

Providing commercial DNA-testing services.

Transferring genetic datasets between multinational companies.

Licensing algorithms trained on genetic information.

Commercialising anonymised genetic research data.

Sharing genomic information for drug discovery.

Receiving royalties from commercial applications developed using genetic datasets.

The central legal question is whether these transactions should be treated as sales of goods, supplies of services, intellectual property royalties, licensing arrangements, research contracts or transfers of intangible commercial rights.

Tax authorities must also consider privacy, informed consent, data ownership, cross-border transfers and the distinction between ownership of biological samples and rights to use information derived from them.

Important distinction: Genetic information is not automatically owned or freely transferable merely because a company has collected or processed it. Legal permission to process information, contractual rights to use it and ownership of intellectual property are separate questions.

2. Legal Nature of Genetic Data Transactions

The tax treatment depends substantially on the legal character of the transaction.

A. Sale of genetic datasets

A biotechnology company may provide a commercial database containing genetic information to another organisation for consideration.

The transaction may raise questions concerning:

Whether the payment represents consideration for a service.

Whether permanent rights or limited access are supplied.

Whether the transaction involves an intellectual property right.

Whether GST or VAT applies.

Whether withholding tax is applicable to cross-border payments.

B. Licensing of genetic information

A company may permit another company to use a genomic database without transferring control of the underlying database.

The agreement may provide limited access, research rights, commercial exploitation rights or exclusive licensing rights.

Tax classification depends on the rights actually granted, not simply the description of the agreement.

C. Genetic research services

Where a laboratory collects samples, sequences DNA, analyses genetic characteristics and provides a report, the transaction will generally have the character of a scientific or professional service.

D. Royalty-based genetic commercialisation

A biotechnology enterprise may receive royalty payments when another company commercially exploits patented inventions, protected software, licensed technology or other intellectual property associated with genetic research.

The payment for access to genetic information itself should not automatically be classified as an intellectual property royalty.

3. Taxation Under Indian Law

India provides an important framework for examining the taxation of genetic data transactions.

A. Income-tax treatment

The Income-tax Act, 1961, governs the taxation of income earned from genetic data commercialisation for relevant historical tax periods. The Income-tax Act, 2025, replaces the 1961 legislation from 1 April 2026.

Depending on the applicable provisions and transaction structure, income may be characterised as:

Business or professional income.

Royalty income.

Fees for technical services.

Capital gains from the transfer of a qualifying capital asset.

Other taxable income.

For example, if an Indian biotechnology company earns ₹50 lakh by providing genomic analysis services to a pharmaceutical company, the receipts may constitute business income.

However, if the payment is for the right to commercially exploit a patented genetic-analysis technology, the royalty provisions may become relevant.

B. Royalty taxation

Section 9(1)(vi) of the Income-tax Act, 1961, contained provisions governing income by way of royalty.

The definition of royalty includes specified payments for the use or right to use intellectual property and certain other rights.

A crucial distinction arises between:

Payment for access to genetic information.

Payment for the use of copyrighted genomic software.

Payment for patented biotechnology.

Payment for technical knowledge or processes.

These payments may receive different tax treatment.

C. Fees for technical services

Section 9(1)(vii) of the Income-tax Act, 1961, dealt with fees for technical services.

Genetic sequencing, specialised genomic analysis, laboratory testing and scientific consultancy may involve technical services.

However, not every digital or scientific transaction automatically constitutes fees for technical services. The nature of the service and applicable statutory requirements must be examined.

D. GST implications

Under India's Central Goods and Services Tax Act, 2017, commercial transactions involving genetic datasets may constitute supplies of services.

Relevant considerations include:

Whether consideration is received.

Whether the transaction occurs in the course or furtherance of business.

Whether the supply qualifies as an export of services.

Whether the recipient is located in India or abroad.

Whether the transaction falls under an applicable exemption.

A commercial genetic-testing service cannot automatically claim exemption merely because it involves healthcare or scientific research.

4. Important Indian Case Laws

The following decisions are particularly relevant by analogy to genetic database licensing, digital information transactions and technical services.

1. Engineering Analysis Centre of Excellence Pvt. Ltd. v. CIT (2021) 432 ITR 471 (SC)

Supreme Court of India

The Supreme Court examined whether payments made to foreign software suppliers constituted royalty under the Income-tax Act and applicable Double Taxation Avoidance Agreements.

The Court held that payments for software distribution or use, without granting rights in the underlying copyright, did not constitute royalty under the relevant treaty provisions.

Relevance to genetic data: If an Indian company merely purchases access to a foreign genomic database without obtaining copyright exploitation rights, the payment should not automatically be treated as royalty. The actual contractual rights and applicable DTAA must be examined.

Indian Kanoon+1

2. CIT v. Skycell Communications Ltd. (2001) 251 ITR 53 (Madras)

The Madras High Court considered whether payments for cellular communication services amounted to fees for technical services.

The judgment emphasised that the mere use of technology or sophisticated equipment does not necessarily mean that technical services have been rendered to the customer.

Relevance: Automated DNA sequencing or routine access to a genomic platform should not automatically be characterised as specialised technical services merely because advanced technology is involved.

PwC

3. CIT v. Kotak Securities Ltd. (2016) 383 ITR 1 (SC)

The Supreme Court considered the character of services provided through an automated stock exchange platform.

The Court distinguished ordinary facilities and standardised services from specialised technical services.

Relevance: A company providing standardised access to a genetic information database may be distinguishable from a company providing customised genomic interpretation, scientific consultancy or specialised research services.

PwC

4. Uptodate Inc. v. DCIT (2023) 150 taxmann.com 231 (Delhi ITAT)

This decision examined subscription payments for access to an online database of healthcare journals and books.

The Tribunal considered the absence of rights to reproduce, modify or commercially exploit the underlying copyrighted material.

It concluded that the subscription receipts did not constitute royalty under the India–US DTAA.

Relevance: This is particularly useful for genomic database businesses. A subscription that merely allows a pharmaceutical company to consult genetic research information may be treated differently from a licence permitting commercial exploitation of protected scientific content.

Digest of case laws+1

5. CIT v. Relx Inc. (2024) 160 taxmann.com 109 (Delhi)

The decision concerned payments for access to an online database and the distinction between database access and technical services.

The reasoning is relevant to the question of whether granting access to collected information amounts to providing technical services.

Relevance: A foreign company supplying access to a genetic research database may not necessarily be providing technical services simply because it has invested expertise in compiling and organising that database. The contractual and operational facts remain decisive.

PwC

5. GST Treatment of Genetic Data Transactions

Under the CGST Act, 2017, the concept of supply is central to determining GST liability.

Relevant provisions include:

Section 7: Scope of supply.

Section 9: Levy and collection of GST.

Section 13: Time of supply of services.

Section 15: Value of taxable supply.

Section 16: Input tax credit.

Section 17: Apportionment and blocked credits.

Section 2(102): Definition of services.

Consider the following illustration.

A biotechnology company provides access to a genetic research database to a pharmaceutical company for ₹20 lakh.

If the arrangement constitutes a taxable supply of services, GST may apply at the applicable rate.

However, the precise treatment depends on the nature of the supply, place of supply, applicable classification and any exemption.

Export of genetic data services

Where an Indian company provides genomic analysis or database services to an overseas customer, the transaction may qualify as an export of services under section 2(6) of the IGST Act, 2017, provided all statutory conditions are satisfied.

Qualifying exports are treated as zero-rated supplies under section 16 of the IGST Act.

A foreign customer alone does not establish export status. The recipient, place of supply, payment and establishment-related conditions must also be examined.

6. International Taxation of Genetic Data Transactions

Cross-border genetic data transactions create additional tax issues.

For example:

An Indian biotechnology company licenses a genomic database to a pharmaceutical company in the United States.

The transaction may raise questions about:

Taxation of royalty payments.

Fees for technical services.

Permanent establishment.

Withholding tax.

Double taxation relief.

Transfer pricing.

Characterisation of intellectual property rights.

A. Double Taxation Avoidance Agreements

A DTAA may determine whether payment received by a foreign company is taxable as royalty, business profits or fees for technical services.

The classification depends on the particular treaty.

For example, a payment for a simple subscription to genomic information may be treated differently from a payment granting rights to reproduce, distribute or commercially exploit copyrighted research material.

B. Withholding tax

Where an Indian company pays a foreign enterprise for genetic data licensing or services, the withholding provisions must be considered.

For relevant transactions under the Income-tax Act, 1961, section 195 required deduction of tax on sums chargeable to tax in India, subject to the applicable rules and treaty provisions.

The tax treatment must be evaluated under the Income-tax Act, 2025, for transactions governed by the new legislation from 1 April 2026.

C. Transfer pricing

Multinational biotechnology companies frequently transfer genetic datasets, research technology and analytical services between associated enterprises.

Such transactions may attract transfer-pricing provisions.

The valuation must consider:

Uniqueness of genetic datasets.

Cost of collection and sequencing.

Accuracy and reliability of information.

Commercial usefulness.

Legal restrictions on data use.

Exclusivity of access.

Research and development expenditure.

Expected commercial benefits.

An artificially low licensing price may result in tax adjustments where the transaction is not consistent with the applicable arm's-length standard.

7. Genetic Data Ownership and Commercial Exploitation: Important International Cases

Taxation cannot be properly understood without examining whether genetic information can legally be commercialised and what rights the parties actually possess.

1. Moore v. Regents of the University of California (1990) 51 Cal. 3d 120

California Supreme Court

The case concerned the commercial development of a cell line from a patient's removed biological tissue without his knowledge of the researchers' commercial interests.

The Court rejected Moore's conversion claim concerning the excised cells but recognised the significance of disclosure obligations and potential conflicts of interest.

Tax significance:

Commercial exploitation of biological material may generate substantial taxable income.

Consent and ownership disputes can affect the legal validity of commercial arrangements.

Researchers and biotechnology enterprises must distinguish biological materials from inventions developed using those materials.

Taxable commercial income does not establish that the original donor has ownership of the resulting invention.

The case is important when analysing the commercialisation of genetic materials and associated financial benefits.

Justia Law+1

2. Greenberg v. Miami Children's Hospital Research Institute 264 F. Supp. 2d 1064 (S.D. Fla. 2003)

The dispute involved genetic research relating to Canavan disease, including the development and commercial patenting of genetic testing technology.

The plaintiffs challenged aspects of the research, informed consent and commercialisation arrangements.

Tax significance:

This case illustrates the importance of examining:

The financial value of donated genetic materials.

Commercial licensing of genetic discoveries.

Patent-related income.

Research agreements and contractual obligations.

The distinction between donations and commercial transactions.

It is not a tax judgment, but it is relevant to the legal foundations of genetic data commercialisation.

3. Washington University v. Catalona 490 F.3d 667 (8th Cir. 2007)

The case involved disputes concerning the control and transfer of biological research materials collected from human donors.

The court examined institutional control and the legal position of donated research materials.

Tax significance:

The decision illustrates why the identity of the legally authorised holder of research materials matters when determining who can enter into commercial agreements and receive related income.

Again, it is relevant by analogy, rather than being a direct tax precedent.

8. Taxation of Different Types of Genetic Data Transactions

The classification is determined by the actual transaction and applicable law, not merely by the label used in the agreement.

9. Taxation of Anonymised and Aggregated Genetic Data

Anonymised genetic datasets create particularly difficult taxation questions.

A biotechnology company may remove identifying information and provide aggregated genetic research information to pharmaceutical manufacturers.

Commercialisation may involve:

Subscription charges.

Research access fees.

Data processing fees.

Licensing payments.

Revenue-sharing agreements.

From a tax perspective, anonymisation does not automatically make a transaction tax-exempt.

The transaction may remain a taxable commercial supply even when the underlying data cannot readily be associated with identifiable individuals.

However, anonymisation does not necessarily eliminate privacy risks. Genetic information may sometimes permit re-identification through comparison with other databases.

10. Data Protection and Tax Compliance

Tax authorities and biotechnology enterprises must distinguish between tax compliance obligations and data protection obligations.

In India, the following legal frameworks are relevant:

A. Digital Personal Data Protection Act, 2023

Where genetic information qualifies as digital personal data, its processing and disclosure must be assessed under the applicable provisions and commencement notifications.

The law's consent, legitimate-use, security and accountability requirements are relevant to commercial genomic databases.

B. Information Technology Act, 2000

Section 43A and the associated Sensitive Personal Data or Information Rules, 2011, have historically been relevant to the protection of sensitive personal information, including specified health and biometric information, subject to the applicable statutory position.

C. Constitutional protection

In Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1, the Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional guarantees.

Relevance: Genetic data transactions involving identifiable individuals must respect privacy and informational autonomy. A tax obligation or commercial contract does not independently authorise unrestricted disclosure of genetic information.

11. Tax Avoidance and Artificial Valuation of Genetic Data

Genetic datasets may have significant economic value, creating opportunities for aggressive tax planning.

Common risks include:

Underpricing genetic databases transferred to foreign subsidiaries.

Artificially allocating intellectual property income to low-tax jurisdictions.

Misclassifying royalties as ordinary database subscriptions.

Misclassifying technical services as simple data access.

Inflating research expenditure to claim excessive deductions.

Creating artificial licensing arrangements between related enterprises.

Transferring valuable genomic intellectual property without appropriate compensation.

Tax authorities may examine the substance of transactions, contractual rights, actual conduct and commercial value.

The OECD Transfer Pricing Guidelines provide an important international framework for analysing transactions involving intangible assets, including difficult-to-value intangibles.

12. Challenges in Taxation of Genetic Data Transactions

Several unresolved legal and regulatory challenges arise in this field.

1. Absence of specific tax classification

Traditional tax laws were not designed specifically for commercial genetic datasets. Consequently, authorities must apply existing rules concerning services, royalties, intellectual property and intangible assets.

2. Difficulty in valuation

A genetic database may become more valuable as its size, diversity and scientific usefulness increase. Determining its fair market value is therefore challenging.

3. Unclear ownership rights

The rights of donors, researchers, laboratories and biotechnology companies may overlap. Ownership of a physical sample does not necessarily establish ownership of the resulting genetic information or inventions.

4. International double taxation

Different countries may classify the same genetic data transaction differently, resulting in disputes over taxing rights.

5. Privacy versus tax enforcement

Tax authorities may require commercial records and financial information, but access to identifiable genetic information raises separate privacy and confidentiality concerns.

6. Artificial intelligence and genetic datasets

Genetic databases may be used to train machine-learning systems. The resulting intellectual property, licensing income and cross-border payments create additional tax classification and valuation difficulties.

13. Suggestions for Legal and Tax Reforms

A comprehensive regulatory framework should consider the following reforms:

Establish clear tax classifications for genetic database licensing.

Develop valuation standards for commercially exploited genomic datasets.

Clarify the treatment of genetic information subscriptions under royalty provisions.

Introduce appropriate transfer-pricing guidance for genomic intangible assets.

Strengthen international cooperation on cross-border genetic data taxation.

Ensure that tax compliance does not undermine genetic privacy.

Establish transparent revenue-sharing arrangements where legally appropriate.

Clarify the distinction between donated biological material, research services and commercial intellectual property.

14. Conclusion

Taxation of Genetic Data Transactions represents an emerging intersection of biotechnology, international taxation, intellectual property, healthcare and data protection law.

The most important legal issue is the correct characterisation of the transaction. A payment for genomic database access may be different from a payment for technical services, a patent licence or the transfer of intellectual property rights.

Indian decisions such as Engineering Analysis Centre of Excellence, Skycell Communications, Kotak Securities and Uptodate Inc. provide useful principles for analysing database access, software licensing and technical service payments.

International cases such as Moore, Greenberg and Washington University v. Catalona provide additional context concerning the commercialisation and control of genetic materials.

The central legal principle is that the taxation of genetic data should depend on the actual economic substance, contractual rights, applicable tax legislation and international tax agreements, while respecting the privacy and legal rights of individuals whose genetic information is involved.

15. Important Case Law Reference Table

Research qualification: None of the above decisions is a direct judicial determination of the taxation of a genetic-data transaction. The tax cases establish analogous principles, while the genetic-material cases provide context concerning commercial rights and control.

16. Important Legislation for Further Study

Income-tax Act, 2025 (India).

Income-tax Act, 1961 (for relevant historical periods).

Central Goods and Services Tax Act, 2017.

Integrated Goods and Services Tax Act, 2017.

Digital Personal Data Protection Act, 2023.

Information Technology Act, 2000.

Patents Act, 1970.

OECD Transfer Pricing Guidelines.

Applicable Double Taxation Avoidance Agreements.

Convention on Biological Diversity and Nagoya Protocol.

For academic or legal research, the distinction between direct tax precedents and cases applied by analogy is particularly important.